Related Experiment Video
Updated: Jun 13, 2025
09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
33.7K
Are 19del and L858R really different disease entities?
Seoree Kim1, Yunseok Heo2, Young-Ho Lee2,3,4,5,6
1Division of Medical Hemato-Oncology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea.
Future Oncology (London, England)
|September 16, 2024
Summary
Understanding epidermal growth factor receptor (EGFR) mutation subtypes like L858R is key. Despite known molecular differences, current treatment strategies for EGFR mutations require evolution to match these distinct biological profiles.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) mutations are common in certain cancers.
- Two main subtypes of common EGFR mutations exist, with recognized similarities and differences.
- Current clinical treatment strategies have not significantly adapted to these subtype distinctions.
Purpose of the Study:
- To explore the molecular nuances of EGFR mutation subtypes, specifically L858R.
- To investigate the impact of receptor protein conformational plasticity and co-occurring mutations on treatment response.
- To highlight the need for evolving treatment strategies based on molecular and biological differences.
Main Methods:
- Analysis of EGFR protein conformational plasticity.
- Evaluation of co-occurring EGFR and non-EGFR mutations.
- Assessment of downstream signaling pathway variations.
Main Results:
- The L858R mutation's behavior is influenced by receptor plasticity and associated mutations.
- Differences in downstream signaling pathways are linked to distinct molecular profiles.
- Molecular distinctions between EGFR mutation subtypes correlate with biological differences.
Conclusions:
- Recognizing molecular differences in EGFR mutations is crucial.
- Current treatment paradigms need to be updated to address subtype-specific biological differences.
- Tailoring therapies based on precise EGFR mutation subtypes and their molecular characteristics is a critical future direction.
